Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Medtronic
AstraZeneca
Merck
Harvard Business School

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LONSURF

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lonsurf

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01896856 Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Recruiting Sidney Kimmel Comprehensive Cancer Center Phase 1/Phase 2 2013-09-01 This is a phase I/randomized phase II study of the combination of SGI-110 and previously treated metastatic colorectal cancer patients. This study will be conducted in two components. First, patients will be enrolled in a phase I study of SGI-110 combined with irinotecan in a standard 3+3 design. After the maximum tolerated dose (MTD) is determined, patients will subsequently be enrolled in a 2:1 randomized phase II study of SGI-110 and irinotecan versus the standard of care regorafenib or TAS-102.
NCT02602327 Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases Recruiting University of California, San Francisco Phase 1 2016-10-01 This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).
NCT02654639 Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Recruiting Georgetown University Phase 2 2016-02-01 Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
NCT02920476 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma Not yet recruiting Taiho Oncology, Inc. Phase 2 2017-02-01 This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell cancer after progression through or intolerance to prior systemic therapy. The trial therapy of TAS-102 is to be administered orally at 35 mg/m2 each dose twice daily. The primary objective of the trial is to determine the progression-free survival, in months, of subjects receiving TAS 102 for the treatment of unresectable or metastatic recurrent squamous non-small cell lung cancers.
NCT02920476 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma Not yet recruiting University of Florida Phase 2 2017-02-01 This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell cancer after progression through or intolerance to prior systemic therapy. The trial therapy of TAS-102 is to be administered orally at 35 mg/m2 each dose twice daily. The primary objective of the trial is to determine the progression-free survival, in months, of subjects receiving TAS 102 for the treatment of unresectable or metastatic recurrent squamous non-small cell lung cancers.
NCT02921737 TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy Not yet recruiting Taiho Oncology, Inc. Phase 2 2017-02-01 This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression through or intolerance to first line chemotherapy. Trial therapy will consist of TAS-102 (Lonsurf®) 35 mg/m2 to be given orally twice daily on days 1-5 and 8-12 with cycles repeating every 28 days. The primary endpoint is to determine the progression free survival (PFS) in subjects with unresectable pancreatic adenocarcinoma.
NCT02921737 TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy Not yet recruiting University of Florida Phase 2 2017-02-01 This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression through or intolerance to first line chemotherapy. Trial therapy will consist of TAS-102 (Lonsurf®) 35 mg/m2 to be given orally twice daily on days 1-5 and 8-12 with cycles repeating every 28 days. The primary endpoint is to determine the progression free survival (PFS) in subjects with unresectable pancreatic adenocarcinoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lonsurf

Condition Name

Condition Name for Lonsurf
Intervention Trials
Stage IVB Colorectal Cancer AJCC v8 4
Stage IVC Colorectal Cancer AJCC v8 4
Stage IVA Colorectal Cancer AJCC v8 4
Colorectal Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lonsurf
Intervention Trials
Colorectal Neoplasms 14
Adenocarcinoma 9
Colonic Neoplasms 6
Rectal Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lonsurf

Trials by Country

Trials by Country for Lonsurf
Location Trials
United States 39
Germany 1
Czechia 1
Belgium 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lonsurf
Location Trials
California 6
Florida 5
Texas 4
Arizona 4
Minnesota 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lonsurf

Clinical Trial Phase

Clinical Trial Phase for Lonsurf
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 15
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lonsurf
Clinical Trial Phase Trials
Not yet recruiting 21
Recruiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lonsurf

Sponsor Name

Sponsor Name for Lonsurf
Sponsor Trials
National Cancer Institute (NCI) 9
Taiho Oncology, Inc. 6
National Comprehensive Cancer Network 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lonsurf
Sponsor Trials
Other 32
Industry 14
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Mallinckrodt
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.